inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level \> upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level \> upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: age ≥ 18 years and ≤ 90 years at the screening assessment weight ≥ 50 kg at randomization hospitalized with a diagnosis of covid-19 and in need of inpatient medical care positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment d-dimer level > upper limit of normal at screening provided electronic or written informed consent, either personally or through a legally authorized representative (lar) must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: age ≥ 18 years and ≤ 90 years at the screening assessment weight ≥ 50 kg at randomization hospitalized with a diagnosis of covid-19 and in need of inpatient medical care positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment d-dimer level > upper limit of normal at screening provided electronic or written informed consent, either personally or through a legally authorized representative (lar) must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: age ≥ 18 years and ≤ 90 years at the screening assessment weight ≥ 50 kg at randomization hospitalized with a diagnosis of covid-19 and in need of inpatient medical care positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment d-dimer level > upper limit of normal at screening provided electronic or written informed consent, either personally or through a legally authorized representative (lar) must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: age ≥ 18 years and ≤ 90 years at the screening assessment weight ≥ 50 kg at randomization hospitalized with a diagnosis of covid-19 and in need of inpatient medical care positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment d-dimer level > upper limit of normal at screening provided electronic or written informed consent, either personally or through a legally authorized representative (lar) must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study, and male patients must be willing to use an effective method of contraception to avoid partner pregnancy and abstain from sperm donation for at least 90 days after last dose

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days of hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. female patients of reproductive or child-bearing potential must be willing to use an effective method of contraception for the duration of the study

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days prior to hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. any woman who suspects she may be pregnant must have a negative pregnancy test prior to randomization. women of child-bearing potential should agree to avoid pregnancy for 3 weeks following randomization

inclusion criteria: 1. age ≥ 18 years and ≤ 90 years at the screening assessment 2. weight ≥ 50 kg at randomization 3. hospitalized with a diagnosis of covid-19 and in need of inpatient medical care 4. positive for sars-cov-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by pcr or validated other test of ongoing infection (not an antibody test for prior exposure), within seven (7) days prior to hospitalization or screening assessment 5. d-dimer level > upper limit of normal at screening 6. provided electronic or written informed consent, either personally or through a legally authorized representative (lar) 7. must agree not to participate in a concurrent interventional study involving anticoagulation or anti-platelet therapy 8. any woman who suspects she may be pregnant must have a negative pregnancy test prior to randomization. women of child-bearing potential should agree to avoid pregnancy for 3 weeks following randomization